ERBB2 and breast cancer: Among younger women (< 50 years) 8666/12,718 (68.1%) BC cases are estimated to be Luminal A-like, 1584 (12.5%) Luminal B-like, 1180 (9.3%) Triple-negative and 661 (5.2%) HER2 enriched.